Susceptibility to therapy-related myelodysplastic syndromes and acute myeloid leukemia

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 3, 2008, Pages 164-165

  Sill, Heinz ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA; GRANULOCYTE COLONY STIMULATING FACTOR; PROTEIN MLH1; PROTEIN MSH2; RECOMBINANT GROWTH FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DNA REPAIR; GENE MUTATION; GENETIC MARKER; GENETIC PREDISPOSITION; HUMAN; INCIDENCE; LEUKEMOGENESIS; MEDICAL RESEARCH; MYELODYSPLASTIC SYNDROME; NONHUMAN; RISK FACTOR; WHOLE BODY RADIATION;

DRUG THERAPY; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PROTO-ONCOGENES; RADIOTHERAPY;

EID: 42049085271     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897-906.
2. Chao RC, Pyzel U, Fridlyand J, et al. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell. 2005;8:337-348.
3. Guillem V, Tormo M. In.uence of DNA damage and repair upon the risk of treatment related leukemia. Leuk Lymphoma. 2008;49:204-217.
4. Knoche E, McLeod HL, Graubert TA. Pharmacogenetics of alkylator-associated acute myeloid leukemia. Pharmacogenomics. 2006;7:719-729.
5. Lawrence JS. Irradiation leukemogenesis. JAMA. 1964;190:93-98.
6. Newman DR, Maldonado JE, Harrison EG, Kiely JM, Linman JW. Myelomono-cytic leukemia in Hodgkin's disease. Cancer. 1970;25:128-134.
7. Ojha RP, Thertulien R, Prabhaker D, Zhou Y, Fischbach LA. A comparative investigation of therapeutic approaches for primary prostate cancer and risk of acute myeloid leukemia. Blood. 2007;110(11):Abstract 1816.
8. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007;25:3871-3876.
9. Ricciardone MD, Özcelik T, Cevher B, et al. Human MLH1 deficiency pre-disposes to hematologic malignancy and neuro.bromatosis type 1. Cancer Res. 1999;59:290-293.
10. Smith SM, LeBeau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43-52.
11. Travis LB. Evaluation of the risk of therapy-associated complications in survivors of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007. 2007:192-196.
12. Whiteside D, McLeod R, Graham G, et al. A homozygous germ-line mutation in the human MSH2 gene predisposes to hematologic malignancies and multiple café-au-lait spots. Cancer Res. 2002;62:359-362.
13. Zebisch A, Staber PB, Delavar A, et al. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res. 2006,66:3401-3408.